Company Overview - Enovis operates as a global medical technology company focused on musculoskeletal health, leveraging a broad product portfolio and established distribution channels to serve healthcare professionals and institutions [5] - The company generates revenue through the sale of proprietary medical devices and solutions, targeting orthopedic specialists, surgeons, physical therapists, and other healthcare providers [7] Recent Developments - On February 18, 2026, Front Street Capital Management, Inc. reported an increase in its position in Enovis by 156,069 shares, valued at approximately $4.61 million [2] - The quarter-end value of Enovis's position rose by $3.40 million, reflecting both the additional shares and share price changes [2] - Enovis shares were priced at $25.42, down 36.5% over the past year, significantly underperforming the S&P 500's roughly 16% gain [6] Financial Performance - Enovis reported full-year revenue of $2.2 billion, representing a 7% increase, with organic growth of 6% [8] - Reconstructive sales climbed by 10%, and adjusted EBITDA reached $403 million [8] - Fourth quarter sales hit $576 million, with adjusted earnings per share of $0.95, exceeding expectations [8] Market Position and Strategy - The recent transaction by Front Street Capital Management indicates a measured turnaround strategy, with Enovis's allocation in the fund representing 1.37% of its 13F assets under management as of December 31, 2025 [6] - The company is guiding for revenue of up to $2.37 billion in 2026, with expectations of higher EBITDA [8][10]